Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin vs dapagliflozin in postmenopausal women with type 2 diabetes and osteopenia
KCT0005710Phase 4Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of DA5221-B2, dapagliflozin in type 2 diabetes mellitus (T2DM), osteopenia, sponsored by Dong-A ST. Started Jul 2021; status: completed.
02
Drugs
DA5221-B2dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)osteopenia
Beyond the preview
Go deeper on KCT0005710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005710.